1 February 2002, vol. 8, no. 1, pp. 19-23(5)
Freedman M S; Blumhardt L D; Brochet B; Comi G; Noseworthy J H; Sandberg-Wollheim M; Soelberg Sørensen P
 Sclerosis Research Clinic, The Ottawa Hospital - General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
 Division of Clinical Neurology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK
 Service de Neurologie, Hôpital Pellegrin, Fédéeration des Neurosciences Cliniques du CHU de Bordeaux, Bordeaux Cedex 33076, France
 Department of Neurophysiology, University of Milan, IRCCS Ospedale San Raffaele, via Olgettina 60, Milan 20132, Italy
 Department of Neurology, Mayo Clinic, Rochester, Minnesota 55095, USA
 Department of Neurology, Lund Hospital, Lund S-22185, Sweden
 Neuroscience Centre, Copenhagen University Hospital, Copenhage D-2100, Denmark
To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit.
An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment.
A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop.
Periodic reviews and modifications
to the statement will be required, as new approaches to the treatment of
MS and other therapeutic agents become available.
© 2002 ingenta